Welcome to our dedicated page for Accendra Health news (Ticker: ACH), a resource for investors and traders seeking the latest updates and insights on Accendra Health stock.
Accendra Health, Inc. reports developments in home-based healthcare products, technology and services delivered through the Apria and Byram Healthcare brands. The company connects patients, providers and insurers across diabetes supplies, sleep health, respiratory care, wound care, urology, ostomy and related patient support categories.
News for ACH centers on quarterly results, guidance, continuing-operations performance after the completed sale of the Products & Healthcare Services business, NYSE ticker changes, debt reduction, maturity extension and other balance-sheet actions tied to its home healthcare platform.
Accendra Health (NYSE: ACH) launched exchange offers for all outstanding 4.500% notes due 2029 and 6.625% notes due 2030 into new 9.000% first-lien 2032 notes and 9.750% second-lien 2033 notes, plus a $326.25 million new-money first-lien issuance.
According to Accendra Health, commitment parties agreed to tender approximately all 2029 notes and about 83% of 2030 notes and to backstop up to $326.25 million of first-lien notes. Early exchange and withdrawal deadlines are June 9, 2026; final expiration is June 22, 2026.
Accendra Health (NYSE: ACH) reported first quarter 2026 results and announced a >$1.5 billion balance sheet optimization backed by existing creditors. The transaction is expected to reduce debt, pay off 2027 maturities, and extend its revolving credit facility.
Q1 2026 continuing operations showed net revenue of $627.8 million, GAAP loss from continuing operations of $6.5 million ($0.08 per share), non-GAAP adjusted net loss of $3.1 million, adjusted EBITDA of $58.4 million, and free cash flow of -$2.0 million. Full-year 2026 net revenue and adjusted EBITDA guidance were reaffirmed.
Accendra Health (NYSE: ACH) will release first-quarter 2026 results on Monday, May 11, 2026 before NYSE trading. A live conference call for investors and analysts is scheduled at 8:30 a.m. EDT the same day with toll-free and toll dial-in numbers and conference ID 1058917.
A simultaneous live webcast is available at the company Investor Relations events page and a replay will be posted after the presentation.
Accendra Health (NYSE: ACH) reported fourth-quarter and full-year 2025 continuing operations results, completing the sale of its Products & Healthcare Services business on December 31, 2025. Full-year revenue was $2.762 billion (+3% vs prior year) with operating cash flow $154 million. The company provided 2026 outlook: revenue $2.55–2.65 billion, adjusted EBITDA $335–355 million, and free cash flow $90–110 million. Cash from the P&HS sale and working-capital improvements increased liquidity; year-end cash and equivalents were $281.99 million. Continuing operations recorded a loss from continuing operations of $102.68 million for 2025. Management emphasized transition, cost controls, and balance sheet optimization.
Accendra Health (NYSE: ACH) will release fourth quarter 2025 financial results on Thursday, February 19, 2026 after NYSE close and will host a conference call at 5:00 p.m. EST the same day.
Dial-in numbers are 1-888-300-2035 (toll-free) and 1-646-517-7437 (toll); conference ID 1058917. A live webcast and later replay are available at the company investor events page: investors.accendra.com/events-and-presentations/.
Accendra Health provides home-based care products and services across diabetes, sleep health, wound care, respiratory care, urology and ostomy under brands Apria and Byram.
Accendra Health (NYSE: ACH) announced that its common stock will begin trading on the New York Stock Exchange under the new ticker ACH effective January 2, 2026, and launched a new corporate website at www.accendrahealth.com. The company also confirmed completion of the sale of its former Products & Healthcare Services business and the Owens & Minor brand on December 31, 2025. The release includes customary Safe Harbor forward-looking language and directs investors to the company’s Form 10-K and subsequent SEC reports for risk factors and additional disclosures.